The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B12
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 66
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_66&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Name:	ifrs-full_CurrentAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Financial Instruments (Narrative) (Details)	12 Months Ended
Financial Instruments (Narrative) (Details)	Aug. 31, 2020 USD ($)	Aug. 31, 2020 CAD ($)	Aug. 31, 2019 CAD ($)	Aug. 31, 2018 CAD ($)	Aug. 31, 2017 CAD ($)
Disclosure of detailed information about financial instruments [abstract]
Preferred shares, redemption premium		5.00%
Total Current Assets		$ 1,677,400	$ 4,965,281
Total Current Liabilities		1,043,819	4,321,273
Working capital		633,581
Deferred flow-through share premium		136,800	47,481	$ 52,157
Adjusted working capital		770,381
Cash and cash equivalents		$ 1,295,723	$ 1,881,841	$ 319,057	$ 1,073,574
Anticipated on-going expenditures to be transacted in US dollars for the next twelve month period	$ 160,000